SCHEMBL2128482

SCHEMBL2128482

CCCCNc1ccncc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM6B O15054 1/20 0.47
KDM4C Q9H3R0 1/20 0.47
ALDH1A1 P00352 2/20 0.47
MAPT P10636 2/20 0.47
POLB P06746 1/20 0.47
HDAC3 O15379 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47
LATS1 O95835 2/20 0.45
LATS2 Q9NRM7 2/20 0.45
TLR8 Q9NR97 1/20 0.44
NAAA Q02083 1/20 0.43
LMNA P02545 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
F2 P00734 1/20 0.42
HTT P42858 1/20 0.42
CTSD P07339 1/20 0.42
CDC7 O00311 1/20 0.42
ROCK2 O75116 1/20 0.42
MAP4K4 O95819 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2352696 0.94 NAAA (0.50) KDM6BKDM4CALDH1A1MAPTPOLB
SCHEMBL11470551 0.92 NAAA (0.53) KDM6BKDM4CALDH1A1MAPTPOLB
SCHEMBL11487106 0.92 NAAA (0.53) KDM6BKDM4CALDH1A1MAPTPOLB
SCHEMBL2262258 0.92 NAAA (0.53) KDM6BKDM4CALDH1A1MAPTPOLB
SCHEMBL863456 0.92 NAAA (0.53) KDM6BKDM4CALDH1A1MAPTPOLB
SCHEMBL25383583 0.92 NAAA (0.53) KDM6BKDM4CALDH1A1MAPTPOLB
SCHEMBL11470674 0.92 NAAA (0.53) KDM6BKDM4CALDH1A1MAPTPOLB
SCHEMBL11470387 0.92 NAAA (0.53) KDM6BKDM4CALDH1A1MAPTPOLB
SCHEMBL11477556 0.92 NAAA (0.53) KDM6BKDM4CALDH1A1MAPTPOLB
SCHEMBL31066871 0.92 NAAA (0.53) KDM6BKDM4CALDH1A1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118382625-A Pyridine [4,3-d ] pyrimidines as TLR7/8 agonists 上海维申医药有限公司 2024-07-23 CN disclosed
US-20230399297-A1 Novel Glutamine Analogs JACOBIO PHARMACEUTICALS CO., LTD (CN) 2023-12-14 US disclosed
US-9951075-B2 Pteridines useful as HCV inhibitors and methods for the preparation thereof JANSSEN SCIENCES IRELAND UC (IE) 2018-04-24 US disclosed
US-9951075-B2 Pteridines useful as HCV inhibitors and methods for the preparation thereof JANSSEN SCIENCES IRELAND UC (IE) 2018-04-24 US disclosed
US-9951075-B2 Pteridines useful as HCV inhibitors and methods for the preparation thereof JANSSEN SCIENCES IRELAND UC (IE) 2018-04-24 US disclosed
US-9834560-B2 Compounds RESPIVERT LTD. (GB) 2017-12-05 US disclosed
US-20170275288-A1 PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF JANSSEN SCIENCES IRELAND UC (IE) 2017-09-28 US disclosed
US-20170275288-A1 PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF JANSSEN SCIENCES IRELAND UC (IE) 2017-09-28 US disclosed
US-20170275288-A1 PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF JANSSEN SCIENCES IRELAND UC (IE) 2017-09-28 US disclosed
US-20170204134-A1 Cyclising Peptides THE UNIVERSITY OF DURHAM (GB) 2017-07-20 US disclosed
US-20090156595-A1 Pteridines useful as HCV inhibitors and methods for the preparation thereof TIBOTEC PHARMACEUTICALS LTD. (IE) 2009-06-18 US disclosed
US-20090156595-A1 Pteridines useful as HCV inhibitors and methods for the preparation thereof TIBOTEC PHARMACEUTICALS LTD. (IE) 2009-06-18 US disclosed
EP-1881834-A1 PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF Tibotec Pharmaceuticals Ltd. (IE) 2008-01-30 EP disclosed
WO-2006120251-A1 PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF TIBOTEC PHARMACEUTICALS LTD. (IE) 2006-11-16 WO disclosed
WO-2006120251-A1 PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF TIBOTEC PHARMACEUTICALS LTD. (IE) 2006-11-16 WO disclosed
WO-2006027211-A1 2,4-SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS GLAXO GROUP LIMITED (GB) 2006-03-16 WO disclosed
EP-0155574-B1 PYRIDINIUM SALTS AND FUNGICIDES AND BACTERICIDES CONTAINING THEM BASF Aktiengesellschaft (DE) 1988-08-24 EP disclosed
EP-0155574-A1 Pyridinium salts and fungicides and bactericides containing them BASF Aktiengesellschaft (DE) 1985-09-25 EP disclosed
US-4107313-A α,α-Bis-[4-(R-amino)-1-pyridinium]xylenes and antibacterial and antifungal uses STERLING DRUG INC. (US) 1978-08-15 US disclosed
US-4067741-A Hardening photographic layers containing silver halide with a 1-sulphonyl-4-amino-pyridinium salt AGFA-GEVAERT, A.G. (DT) 1978-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399297-A1 Novel Glutamine Analogs GLUL, GATD3, GLS KDM6B 1692/4885KDM4C 1237/4885ALDH1A1 4320/4885
US-20170275288-A1 PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF HCCS, HAVCR2, MAVS KDM6B 1703/4885KDM4C 1116/4885ALDH1A1 2019/4885
US-20170204134-A1 Cyclising Peptides VIP, NGLY1, NPPA KDM6B 4838/4885KDM4C 4831/4885ALDH1A1 4866/4885
US-20090156595-A1 Pteridines useful as HCV inhibitors and methods for the preparation thereof HCCS, HAVCR2, MAVS KDM6B 1703/4885KDM4C 1116/4885ALDH1A1 2019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.